Dibenzepin

Summary

Dibenzepin (CHEMBL1442422) is an approved small molecule (ATC N06AA08); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AA08
• Indications: 1 condition
• Chemistry: 295.4 Da · C18H21N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1442422
Name	Dibenzepin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9419
ATC	N06AA08
Molecular formula	C18H21N3O
Molecular weight	295.4
InChIKey	QPGGEKPRGVJKQB-UHFFFAOYSA-N

SMILES: CN1C2=CC=CC=C2C(=O)N(C3=CC=CC=C31)CCN(C)C

IUPAC name: 5-[2-(dimethylamino)ethyl]-11-methylbenzo[b][1,4]benzodiazepin-6-one

Also known as: Dibenzepin, Dibenzepina, Dibenzepine, SID26754618, SID29216076, DIBENZEPIN, dibenzepin

Parent form; salt/anhydrous children: CHEMBL2104287

Patent coverage: 967 distinct patent families (3,679 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,550 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Histamine H1 receptor, Mu-type opioid receptor, D(3) dopamine receptor, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 6.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 19 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	7.7	Ki	20	nM	CHEMBL_ACT_22401780
MAPT	6.8	Potency	158.5	nM	CHEMBL_ACT_4503991
SLC6A2	6.67	AC50	211.8	nM	CHEMBL_ACT_25145740
HTR1A	6.51	AC50	306	nM	CHEMBL_ACT_25164764
SLC6A4	5.88	AC50	1320	nM	CHEMBL_ACT_25151067
HTR1A	5.6	Ki	2500	nM	CHEMBL_ACT_22401755
CHRM2	5.58	AC50	2621	nM	CHEMBL_ACT_25195476
HTR6	5.48	Ki	3300	nM	CHEMBL_ACT_22401743
HTR2A	5.14	Ki	7200	nM	CHEMBL_ACT_22401749
ADRA2A	5.02	AC50	9474	nM	CHEMBL_ACT_25156169

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).